Nov 02, 2023

Aculys Pharma Announces Leadership Change

Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today announced that Kazunari Tsunaba will be leaving his position as Chief Executive Officer. Takeshi Takahashi, a co-founder, and a member of the Board will be acting as interim Chief Executive Officer effective immediately. Mr. Takahashi will lead the Aculys senior management team through the transition.

About Aculys Pharma, Inc.

Aculys is a clinical stage biopharmaceutical company focused on the commercialization of neurology innovations for patients in Japan. Aculys was formed in 2021 to catalyze innovative treatments for neurological and psychiatric disorders. We are committed to shortening the drug lag in Japan by developing and commercializing novel CNS treatments; applying blockchain and AI technologies to increase speed to market; and providing services to improve medical care for patients, their families, healthcare professionals, and society.

Company name: Aculys Pharma, Inc.
Location: The ARGYLE Aoyama 6F, 2-14-4 Kita-Aoyama, Minato-ku, Tokyo
Representative: Takeshi Takahashi
Establishment date: January 2021
URL：https://www.aculys.com